drugset / Trial / NCT05601128
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
Phase 3
Completed
12 enrolled
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of CABENUVA (Long-acting Cabotegravir Plus Long-acting Rilpivirine) in patients with HIV infection and severe renal impairment. This study is considered research and is voluntary.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2025-04-01
- Completion
- 2025-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabotegravir | Small molecule | 30 mg | Oral |
| Subject | Cabotegravir | Small molecule | 400 mg | Oral |
| Subject | Cabotegravir | Small molecule | 600 mg | Oral |
| Subject | Rilpivirine | Small molecule | 25 mg | Oral |
| Subject | Rilpivirine | Small molecule | 600 mg | Oral |
| Subject | Rilpivirine | Small molecule | 900 mg | Oral |